Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Aurore Perrot et al.|Nature Medicine|2024Cited by 109
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Jill Corre, Aurore Perrot et al.|Blood|2025Cited by 15